Alpha Sense BI

AUGUST 30, 2023

As time goes on and more firms adopt AI tools, these capabilities will become even more essential to maintain a competitive advantage. Now integrated into nearly every industry, genAI is fast becoming a must-have for any firm that aims to get the competitive edge.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

MAY 5, 2023

2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. Three years later, despite macroeconomic uncertainties, investors remain attracted to this space, particularly the more innovative and tech-influenced sub-sectors like biotech and MedTech.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 29, 2024

Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

2023 was all about learning the use cases of genAI, as companies raced to introduce their own genAI offerings and capabilities into a fiercely competitive market (i.e. trillion market evaluation by 2032 due to the ever-increasing number of companies integrating this technology. OpenAI’s ChatGPT ). Start your free trial today.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

APRIL 12, 2024

Generally, expert calls provide investment researchers with the operator’s perspective, which is critical to understanding competitive moats and enhancing data-driven research with soft data. You think, ‘I have competitively a better methodology, a better framework, and you think the world will go on it.’ It’s one of those things.

Primary Research 52

Primary Research Advantage Advantage Research 52

Engage3

MAY 19, 2022

He has a wealth of cross-industry experience in accelerating companies’ growth and raising capital, having spent more than fifteen years in SaaS companies as CFO and COO in industries as varied as manufacturing and biotech. Adi received his B.S. in Applied Mathematics and B.A. Helena Cisneros Sr. He holds B.A. He is also an entrepreneur.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

MARCH 13, 2024

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59